New book by Larry Connors Click here Improve your trading - See how
Cura will supply and distribute Mucotrol(TM) with Medivisor handling the marketing and sales. Under the terms of the new agreement both parties agree to now share in the net profits.
"We are pleased to have signed this new sales and marketing agreement with Cura," stated Dino Luzzi, CEO of Medivisor. "We believe Mucotrol will demonstrate strong commercial interest in the relief of side effects of those patients undergoing chemotherapy treatments."
About Medivisor Inc.: Medivisor is a medical communications company dedicated to providing concise and timely medical information to healthcare industry professionals. Medivisor exclusively serves the bioscience and pharmaceutical markets, offering specialized medical marketing consulting, graphic design, web site marketing strategy and market research.
About Cura Pharmaceutical: Cura is a privately held pharmaceutical business that develops, distributes and sells innovative and generic pharmaceuticals. It focuses on selected niche specialty markets through the offering of distinctive products and services, which provide distinct unmet medical needs.
About Mucotrol(TM): Mucotrol(TM) is prescribed for the management and relief of pain for Mucositis, which may be caused by chemotherapy or radiotherapy and irritation due to oral surgery. The National Cancer Institute estimates that approximately 300,000 cancer patients in the U.S. suffer from mucositis associated with cancer treatments.
Safe Harbor
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act") including those relating to the roll-out of Cura Pharmaceutical's Mucotrol. Additionally, words such as "seek," "intend," "believe," "plan," "estimate," "expect," "anticipate" and other similar expressions are forward-looking statements within the meaning of the Act. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the performance ability of the initial units in the field. Further information on Medivisor risk factors is contained in its filings with the Securities and Exchange Commission. Medivisor does not undertake any duty nor does it intend to update the results of these forward-looking statements.
Contact: Dino Luzzi CEO Medivisor Inc. 326 Walt Whitman Road Huntington Station, N.Y. 11746 Tel: 631.549.7100 Email Contact
SOURCE: Medivisor Inc.
http://www2.marketwire.com/mw/emailprcntct?id=DA6D911380EE44FB
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
15260 Ventura Blvd., Ste. 2200
Sherman Oaks, CA 91403
© Copyright 2009 The Connors Group, Inc.
